Osborne Clarke in Amsterdam has advised investors Ancora Finance Group and Wellington Partners in respect of the spin out transaction of Koa Health from Alpha, Telefónica’s moonshot factory and the first closing of the up to EUR 30 million Series A financing round.
Koa Health is a digital mental healthcare provider redefining care by offering a range of personalised mental health solutions backed by science and designed to improve user wellbeing. Headquartered in the Netherlands, Koa Health has operations in Barcelona, the US and the UK.
Koa Health’s spin out from Telefónica supports the company’s ambition to expand internationally and scale to meet the rapidly growing demand for digital mental health products and better serve individuals’ needs. Nearly 1 billion people worldwide are living with a mental disorder according to the World Health Organisation, which has called for substantial investment to avert a global mental health crisis accelerated by the COVID-19 pandemic. There has never been a greater need for digital solutions to support individuals’ mental health.
The Osborne Clarke in Amsterdam team was led by Partner Herke van Hulst and included Senior Associate Geoffrey Beurskens and Maurits Hofman (Corporate M&A), Partner Job van der Pol, Senior Associate Cees Graafland and Aram Hovanesjan (Tax), Associate Director Mechteld Flohil (Candidate Civil-Law Notary), Senior Associate Coen Barneveld Binkhuysen and Associate Marleen Huisman (Commercial Contracting/IP), Partner Jorgo Tsiris and Wyke Schilstra (Employment) and Partner Anna Williams and Senior Associate Joanne Loveridge (Commercial Contracting) from Osborne Clarke in the UK.
Osborne Clarke has a market-leading international venture capital practice and is widely recognized as a leading European law firm for companies operating in the life science and healthcare sector. Its digital health sector team has a strong track record of providing highly sophisticated advice to investors and digital health clients on cutting-edge issues, across multiple service lines. Recent notable work from Osborne Clarke’s life science sector this year includes advising LAVA Therapeutics on its USD 83 million Series C financing round, the investors on the EUR 32 million Series B financing round in VarmX, advising iOnctura on closing its EUR 20.1 Series A financing round, advising on Terumo’s acquisition of Quirem Medical and advising Grifols on its acquisition of a 10% stake in Bloodbuy, a cloud-based marketplace for blood products.